Blood Reviews
Volume 17, Issue 1 , Pages 1-6 , March 2003

Thromboembolic diseases of childhood

  • S. Revel-Vilk

      Affiliations

    • Division of Hematology/Oncology, Pediatric Thrombosis and Haemostasis Program, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ont., Canada M5G IX8
    • ,
  • P. Massicotte

      Affiliations

    • Division of Hematology/Oncology, Pediatric Thrombosis and Haemostasis Program, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ont., Canada M5G IX8
    • Population Health Science, The Hospital for Sick Children, University of Toronto, Toronto, Ont., Canada M5G IX8
    • Corresponding Author InformationCorrespondence to: P. Massicotte, Division of Hematology/Oncology, Pediatric Thrombosis and Haemostasis Program, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ont., Canada M5G IX8. Tel.: +1 416 813 7977; fax: +1 416 813 8719

References 

  1. Andrew M, Michelson AD, Bovill T, et al.  The prevention and treatment of thromboembolic disease in children: a need for thrombophilia programs. J. Pediatr. Hematol. Oncol. 1997;19:7–22
  2. Streif W, Andrew ME. Venous thromboembolic events in pediatric patients. Diagnosis and management. Hematol. Oncol. Clin. North Am. 1998;12:1283–1312
  3. Andrew M, David M, deVeber G, Brooker LA. Arterial thromboembolic complications in paediatric patients. Thromb. Haemost. 1997;78:715–725
  4. Andrew M, David M, Adams M, et al.  Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251–1257
  5. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J. Pediatr. 2001;139:676–681
  6. Monagle P, Adams M, Mahoney M, et al.  Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr. Res. 2000;47:763–766
  7. Prandoni P, Lensing WA, Cogo A, et al.  The long term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 1996;125:1–7
  8. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 1995;96:939–943
  9. Nowak-Göttl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch. Dis. Child Fetal. Neonatal. Ed. 1997;76:F163–F167
  10. Heller C, Schobess R, Kurnik K, et al.  Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors – a multicentre case-control study. Br. J. Haematol. 2000;III:534–539
  11. Bokenkamp A, von Kries R, Nowak-Göttl U, Gobel U, Hoyer PF. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur. J. Pediatr. 2000;159:44–48
  12. Adcock D, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminants. Semin. Thromb. Haemost. 1990;69:283–292
  13. Auletta MJ, Headington JT. Purpura fulminans: a cutaneous manifestation of severe protein C deficiency. Arch. Dermatol. 1988;124:1387–1391
  14. Berube C, Mitchell L, Silverman E, et al.  The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr. Res. 1998;44:351–356
  15. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al.  Medical progress: oral contraceptives and the risk of venous thrombosis. N Engl. J. Med. 2001;344:1527–1535
  16. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin. Thromb. Hemost. 1997;23:271–280
  17. Borgna-Pignatti C, Carnelli V, Caruso V, et al.  Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta. Haematol. 1998;99:76–79
  18. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J. Pediatr. 1998;133:770–776
  19. Andrew M, Marzinotto V, Pencharz P, et al.  A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J. Pediatr. 1995;126:358–363
  20. Talbott GA, Winters WD, Bratton SL, O’Rourke PP. A prospective study of femoral catheter-related thrombosis in children. Arch. Pediatr. Adolesc. Med. 1995;149:288–291
  21. Beck C, Dubois J, Grignon A, Lacroix J, David M. Incidence and risk factors of catheter related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J. Pediatr. 1998;133:237–241
  22. Mitchell L, Abshire T, Hanna K, Andrew M, for the PARKAA investigators. A prospective cohort determinating the incidence of thrombotic events in children with acute lymphoblastic leukemia treated with l-asparginase: results of the PARKAA study. Blood 1999; 94: 649a
  23. Mitchell L, Chait P, Ginsberg J, Hanna K, Andrew M. Comparison of venography with ultrasound for detection of venous thrombosis in the upper body in children: results of the PARKAA study. Blood. 1999;94:588a
  24. Andrew M, PROTEKT Investigators. A randomized control trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Blood 2000; 96: 492a
  25. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med. 2000;26:967–972
  26. Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutanous cardiac catheterization in children. Circulation. 1974;50:565–569
  27. Hentschel R, Wiescholek U, von Lengerke J, Harms E, Jorch G. Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis – a prospective study. Eur. J. Pediatr. 1999;158(Suppl. 3):S126–S129
  28. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 2001;119:S344–S370
  29. Sade RM, Crawford FA, Fyfe DA, Stroud MR. Valve prostheses in children: a reassessment of anticoagulation. J. Thorac. Cardiovasc. Surg. 1988;95:553–561
  30. Solymar L, Rao PS, Mardini MK, Fawzy ME, Guinn G. Prosthetic valves in children and adolescents. Am. Heart J. 1991;121:557–568
  31. deVeber G, Andrew M. Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl. J. Med. 2001;345:417–423
  32. Lancon JA, Killough KR, Tibbs RE, Lewis AI, Parent AD. Spontaneous dural sinus thrombosis in children. Pediatr. Neurosurg. 1999;30:23–29
  33. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch. Neurol. 1999;56:967–971
  34. Veilhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf N, Nowak-Göttl U. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur. J. Pediatr. 1998;157:555–560
  35. Heller C, Becker S, Scharrer I, Kreuz W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur. J. Pediatr. 1999;158(Suppl. 3):S117–S121
  36. Schoenberg BS, Mellinger JF, Schoenberg DF. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology. 1978;28:763–768
  37. Broderick J, Talbot TG, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracereblar hemorrhage. J. Child Neurol. 1993;8:250–255
  38. deVeber G, Monagle P, Chan A, et al.  Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch. Neurol. 1998;55:1539–1543
  39. Becker S, Heller C, Gropp F, Scharrer I, Kreuz W. Thrombophilic disorders in children with cerebral infarction. Lancet. 1998;352:1756–1757
  40. Askalan R, Laughlin S, Mayank S, et al.  Chickenpox and stroke in childhood: a study of frequency and causation. Stroke. 2001;32:1257–1262
  41. Chabrier S, Husson B, Lasjaunias P, Landrieu P, Tardieu M. Stroke in childhood: outcome and recurrence risk by mechanism in 59 patients. J. Child Neurol. 2000;15:290–294
  42. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin. Thromb. Hemost. 2000;26:335–340
  43. Zenz W, Bodo Z, Plotho J, et al.  Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb. Haemost. 1998;80:763–766
  44. Kenet G, Sadetzki S, Murad H, et al.  Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31:1283–1288
  45. Nowak-Göttl U, Strater R, Heinecke A, et al.  Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94:3678–3682
  46. Lanthier S, Carmant L, David M, Larbrisseau A, de Veber G. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. Neurology. 2000;54:371–378
  47. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J. Child Neurol. 2000;15:316–324
  48. Lane DA, Mannucci PM, Bauer KA, et al.  Inherited thrombophilia: part I. Thromb. Haemost. 1996;76:651–662
  49. Pineo GF, Hull RD. Thrombophilia: disorders predisposing to venous thromboembolism. Baill. Clin. Haematol. 1998;II:525–540
  50. Michiels JJ, Hamulyak K. Laboratory diagnosis of hereditary thrombophilia. Semin. Thromb. Hemost. 1998;24:309–320
  51. Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul. Fibrinolysis. 1999;10:251–259
  52. von Depka M, Nowak-Göttl U, Elsert R, et al.  Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96:3364–3368
  53. Kraaijenhagen RA, Anker PS, Koopman MMW, et al.  High plasma concentration of factor VIIIc is a major risk factors for venous thromboembolism. Thromb. Haemost. 2000;83:5–9
  54. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl. J. Med. 2000;342:696–701
  55. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678–3682
  56. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single center. Arch. Dis. Child. 1999;81:176–178
  57. Ehrenfoth S, Junker R, Koch HG, et al.  Multicenter evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur. J. Pediatr. 1999;158(suppl 3):S97–104
  58. Hagstrom JN, Walter J, Bluebond-Langner R, Amatniek JC, Manno CS, High KA. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease. J. Pediatr. 1998;133:777–781
  59. Bonduel M, Hepner M, Sciuccati G, Torres AF, Pieroni G, Frontroth JP. Prothrombotic abnormalities in children with venous thromboembolism. J. Pediatr. Hematol. Oncol. 2000;22:66–72
  60. Revel-Vilk S, Chan A, Knapp C, et al.  Incidence of congenital prothrombotic disorders in children with venous thromboembolic disease: a prospective cohort study. Blood. 2001;98:50a
  61. Wermes C, von Depka-Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of gentic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur. J. Pediatr. 1999;158(Suppl. 3):S143–S146
  62. Nowak-Göttl U, Dubbers A, Kececioglu D, et al.  Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J. Pediatr. 1997;131:608–612
  63. Kosch A, Junker R, Kurnik K, et al.  Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb. Res. 2000;99:531–537
  64. Nowak-Göttl U, Junker R, Kreuz W, et al.  Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858–862
  65. Manco-Johnson MJ. Disorders of hemostasis in childhood: risk factors for venous thromboembolism. Thromb. Haemost. 1997;78:710–714
  66. Segel GB, Francis CA. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cells Mol. Dis. 2000;26:540–560
  67. Chan AK, deVeber G. Prothrombotic disorders and ischemic stroke in children. Semin. Pediatr. Neurol. 2000;7:301–308
  68. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin. Chem. 2001;47:1597–1606
  69. Martinelli I, Mannucci PM, De Stefano V, et al.  Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353–2358
  70. Bucciarelli R, Rosendaal FR, Tripodi A, et al.  Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler. Thromb. Vasc. Biol. 1999;19:1026–1033
  71. Simioni P, Sanson BJ, Pradoni P, et al.  Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb. Haemost. 1999;81:198–202
  72. Sanson BJ, Simioni P, Tormene D, et al.  The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C or protein S: a prospective cohort study. Blood. 1999;94:3702–3706
  73. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu. Rev. Med. 2000;51:169–185
  74. Sutor AH, Uhl M. Diagnosis of thromboembolic disease during infancy and childhood. Semin. Thromb. Hemost. 1997;23:237–246
  75. Anton N, Massicotte P. Venous thromboembolism in pediatrics. Semin. Vasc. Med. 2001;I:111–121
  76. Hirsh J, Warkentin TE, Shaughnessy SG, et al.  Heparin and low-molecular-weight heparin:mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:S64–S94
  77. Andrew M, Mitchell L, Vegh R, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb. Haemost. 1994;72:836–842
  78. Streif W, Mitchell LG, Andrew M. Antithormbotic therapy in children. Curr. Opin. Pediatr. 1999;11:56–64
  79. Andrew M, Marzinotto V, Massicotte P, et al.  Heparin therapy in pediatric patients: a prospective cohort study. Pediatr. Res. 1994;35:78–83
  80. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients – a review of the literature and a new case treated with dansproid sodium. Eur. J. Pediatr. 1999;158(suppl 3):S130–S133
  81. Avioli L. Heparin induced osteoporosis: an appraisal. Adv. Exp. Med. Biol. 1975;52:375–387
  82. Dix D, Andrew M, Marzinotto V, et al.  The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J. Pediatr. 2000;136:439–445
  83. Punzalan RC, Hillery CA, Montgomery RR, Scott JP, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J. Pediatr. Hematol. Oncol. 2000;22:137–142
  84. Weitz JI. Low molecular weight heparins. N Engl. J. Med. 1997;337:688–698
  85. Hirsh J, Dalen JE, Anderson DR, et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:S8–S21
  86. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 1994;121:676–683
  87. Andrew M, Marzinotto V, Brooker LA, et al.  Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb. Haemost. 1994;71:265–269
  88. Streif W, Andrew M, Marzinotto V, et al.  Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94:3007–3014
  89. Schmidt B, Andrew M. Report of scientific and standardization subcommittee on neonatal hemostasis diagnosis and treatment of neonatal thrombosis. Thromb. Haemost. 1992;67:381–382
  90. Marzinotto V, Monagle P, Chan A, et al.  Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr. Cardiol. 2000;21:347–352
  91. Hooshang T, Capitanio M. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology. 1990;176:728–730
  92. Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy. Thromb. Haemost. 1999;Suppl.:1333a
  93. Chalmers EA, Gibson BE. Thrombolytic therapy in the management of paediatric thromboembolic disease. Br. J. Haematol. 1999;104:14–21
  94. Robinson A, Fellows KE, Bridges ND, Rome JJ. Effectiveness of pharmacomechanical thrombolysis in infants and children. Am. J. Cardiol. 2001;87:496–499
  95. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J. Pediatr. 2001;139:152–156
  96. Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb. Haemost. 1996;76:132–134
  97. Gupta AA, Leaker M, Andrew M, et al.  Safety and outcome of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J. Pediatr. 2001;139:682–688

PII: S0268-960X(02)00007-3

Blood Reviews
Volume 17, Issue 1 , Pages 1-6 , March 2003

Article Tools